Ingalls & Snyder LLC Vertex Pharmaceuticals Inc Transaction History

Ingalls & Snyder LLC

$2.33 Billion
Q2 2024

A detailed history of Ingalls & Snyder LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ingalls & Snyder LLC holds 927 shares of VRTX stock, worth $465,771. This represents 0.02% of its overall portfolio holdings.

Number of Shares

927

Previous 1,033 10.26%

Holding current value

$465,771

Previous $432,000 0.69%

% of portfolio

0.02%

Previous 0.02%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$392.81 - $485.53 $41,637 - $51,466	-106 Reduced 10.26%	927 $435,000
Q4 2023 Jan 29, 2024	BUY	$343.0 - $410.68 $9,947 - $11,909	29 Added 2.89%	1,033 $420,000
Q2 2022 Aug 11, 2022	SELL	$234.96 - $292.55 $1,644 - $2,047	-7 Reduced 0.69%	1,004 $283,000
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $885 - $1,043	4 Added 0.4%	1,011 $264,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $178,249 - $225,014	1,007 New	1,007 $221,000
Q3 2021 Oct 27, 2021	SELL	$181.39 - $202.99 $182,659 - $204,410	-1,007 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$187.49 - $221.1 $36,185 - $42,672	-193 Reduced 16.08%	1,007 $203,000
Q2 2020 Jul 31, 2020	SELL	$225.48 - $295.8 $552,426 - $724,710	-2,450 Reduced 67.12%	1,200 $348,000
Q1 2020 Apr 22, 2020	BUY	$199.77 - $247.81 $489,436 - $607,134	2,450 Added 204.17%	3,650 $869,000
Q1 2019 Apr 11, 2019	BUY	$163.73 - $194.7 $196,476 - $233,640	1,200 New	1,200 $221,000
Q4 2018 Jan 24, 2019	SELL	$151.91 - $192.21 $182,292 - $230,652	-1,200 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $174,864 - $203,952	1,200 New	1,200 $204,000
Q4 2017 Jan 19, 2018	SELL	$137.28 - $155.55 $448,905 - $508,648	-3,270 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$148.13 - $162.24 $484,385 - $530,524	3,270	3,270 $497,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Account

Ingalls & Snyder LLC Vertex Pharmaceuticals Inc Transaction History